CurrentBlue Cross Blue Shield - TennesseePolicy N/A

Metabolite Markers of Thiopurines Testing

Guidance on use of TPMT and NUDT15 testing and thiopurine metabolite measurement to inform thiopurine dosing and monitoring in IBD and related indications; intended for clinicians ordering laboratory testing and for reimbursement decision-making.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyMetabolite Markers of Thiopurines Testing

Policy CodePolicy N/A

Change TypeNo material clinical or coverage changes

Effective DateN/A

Next Review DateN/A

Key ActionOrder TPMT (and consider NUDT15) testing prior to initiating thiopurines; use metabolite testing reactively for toxicity, inadequate response, or suspected nonadherence.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3guideline groups cited

3procedure codes listed

2genetic targets

Severalrecommended clinical scenarios

~20references

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

pharmacogenetic targets

Coverage criteria and guideline-based indications

Guideline-based testing scenarios

Testing recommended or suggested by cited professional guidelines in the following scenarios:

Pre-initiation TPMT testing: TPMT testing is recommended before initiation of thiopurines to identify individuals with extremely low or absent TPMT activity who should avoid thiopurines due to risk of severe leukopenia.

NASPGHAN, BSG, and other societies recommend TPMT assessment prior to starting therapy.

NUDT15 testing or monitoring: Test NUDT15 genotype when available; for indeterminate or unknown NUDT15 status and if thiopurines are required, monitor closely for toxicity.

CPIC and BSG acknowledge NUDT15 variants that influence thiopurine tolerance and recommend testing if available or close monitoring if status is unknown.

Reactive thiopurine metabolite testing: Perform thiopurine metabolite (6-TG and/or 6-MMP) testing to investigate suspected thiopurine toxicity (eg, myelotoxicity, newly abnormal LFTs), inadequate clinical response on a stable dose, suspected nonadherence, or to guide dose optimization in active disease.

AGA, ECCO/ESPGHAN, BSG and NASPGHAN support reactive metabolite testing in these scenarios rather than routine surveillance.

Avoid routine repetitive metabolite testing in stable patients: Do not perform routine or repetitive thiopurine metabolite monitoring in patients who are clinically stable and doing well on an acceptable thiopurine dose.

NASPGHAN and AGA advise against routine monitoring in quiescent disease; evidence does not support proactive monitoring for all unselected patients in remission.

Guideline authors do not support routine proactive monitoring of thiopurine metabolites in unselected patients. The American Gastroenterological Association (AGA) suggests against routine thiopurine metabolite monitoring in adult patients with quiescent IBD, and NASPGHAN states that routine and repetitive metabolite testing has little or no role in patients who are doing well on an acceptable thiopurine dose.

No explicit coverage exclusions are stated in the referenced bibliography excerpts provided; the citation list includes foundational studies and society guidelines but does not present discrete exclusion language identifying specific tests or indications as excluded from coverage.

Proactive therapeutic drug monitoring of thiopurine metabolites for all unselected patients in remission (routine surveillance) is not supported by the cited evidence and guideline authors. Both the NASPGHAN consensus and the AGA guidance emphasize reactive metabolite testing for active disease, adverse effects, suspected nonadherence, or inadequate response rather than routine monitoring in patients in remission.

Within the provided reference list excerpts there are no explicit statements phrased as 'not medically necessary.' The bibliographic material and guideline summaries describe recommendations and suggested uses but do not include formal 'not medically necessary' declarations in these chunks.

Indications supported for testing

Pre-treatment TPMT assessment and reactive metabolite testing

Covered when ANY of the following indications are documented in the medical record:

Pre-treatment high-risk identification: TPMT assessment (genotype or erythrocyte enzymatic activity) performed prior to initiating thiopurine therapy to identify individuals with low or absent TPMT activity at high risk for severe myelotoxicity.

Recommended by NASPGHAN, BSG, and other guideline groups.

Evaluation of suspected thiopurine toxicity: Thiopurine-related toxicity evaluation including myelotoxicity (eg, unexplained leukopenia) or newly abnormal liver function tests where metabolite testing or TPMT/NUDT15 assessment will inform management.

BSG and ECCO/ESPGHAN recommend checking metabolites with myelotoxicity or elevated transaminases.

Inadequate clinical response on stable dose: Measurement of thiopurine metabolites (6-TG and 6-MMP) to assess pharmacologic exposure and guide dose adjustment in a patient with incomplete response while on a stable thiopurine dose.

Non-supported uses and exclusions

Proactive or routine thiopurine metabolite monitoring for all unselected patients in remission is regarded by guideline authors as unsupported by available evidence and therefore is not recommended as a routine policy-driven practice. The AGA explicitly suggests against routine monitoring in quiescent adult patients, and NASPGHAN advises that routine/repetitive testing has little or no role in patients doing well.

No specific tests, assay names, or clinical indications are explicitly listed as definitively 'not covered' in the provided bibliography excerpts; the reference material supplies background studies and guideline documents rather than precise exclusion lists.

Applicable procedure and billing codes

Applicable CPT/HCPCS Procedure CodesCPT

80299	Quantitation of therapeutic drug, not elsewhere specified.
82657	Enzyme activity in blood cells, cultured cells, or tissue, not elsewhere specified; nonradioactive substrate, each specimen.
84433	Thiopurine S-methyltransferase (TPMT)

Provider obligations, authorization, and documentation

Prior Authorization

Prior authorization may be required

BlueCross BlueShield of Tennessee may require prior authorization for testing associated with the listed procedure codes. Providers should verify benefit coverage and authorization requirements before ordering tests to avoid claim denials.

Affected CPT/HCPCS codes: 80299, 82657, 84433

Note

Government policy supersedes

If there is a conflict between this policy and any applicable government coverage (e.g., Local Coverage Determination, National Coverage Determination, or state Medicaid policy), the government policy takes precedence and will be used to make the coverage determination.

Documentation Required

Documentation required to support testing

Who may order tests and laboratory considerations

Note

No specific ordering-provider restrictions; tests may be LDTs

No provider-type restrictions for ordering are specified in the extracted sections; tests referenced may be laboratory-developed tests performed by high-complexity laboratories under CLIA regulations.

LDTs are regulated as high-complexity tests under CLIA '88 and are often performed and validated in-house by reference laboratories.

Note

No specification of who may order testing (specialist vs primary care)

The policy and cited chunks do not specify which clinician types (specialist versus primary care) are authorized to order TPMT, NUDT15, or thiopurine metabolite testing.

Testing frequency and repetition limits

inv-23: Thiopurine metabolite testing — routine monitoring guidance

Policy guidanceRoutine or repetitive thiopurine metabolite testing is not recommended in clinically stable patients who are doing well on an acceptable thiopurine dose.

Reasoning from guidelinesNASPGHAN and AGA advise that routine/repetitive metabolite testing has little or no role in patients who are doing well; evidence does not support proactive monitoring in all unselected patients in remission.

When testing is appropriateUse metabolite testing reactively to investigate toxicity, inadequate response, suspected nonadherence, or to guide dose adjustments in active disease.

inv-24: Frequency limits

Frequency limit (general)No routine repetitive testing in clinically stable patients (no specific numeric interval mandated).

Reactive monitoring timing

Clinical background and rationale

Thiopurines (azathioprine, mercaptopurine, thioguanine) are commonly used in inflammatory bowel disease and other immunologic conditions. Variants in TPMT and NUDT15, and measurement of thiopurine metabolites (6‑TG and 6‑MMP), inform risk stratification and management. Professional guidelines recommend TPMT assessment prior to thiopurine initiation to identify individuals with low or absent TPMT activity who are at high risk for severe myelotoxicity, and they endorse reactive metabolite testing to investigate toxicity, inadequate response on a stable dose, or suspected nonadherence rather than routine surveillance in clinically stable patients.

Key definitions and guideline references

inv-16: TPMT testing — definition

DefinitionTPMT testing: genotype or erythrocyte enzymatic activity assay to identify patients with low or absent thiopurine methyltransferase activity who are at increased risk for severe thiopurine toxicity.

PurposeIdentify homozygous or extremely low TPMT activity individuals who should avoid thiopurines due to risk of significant leukopenia.

Complementary monitoringEven with TPMT testing, routine CBC/WBC monitoring is still required because TPMT testing does not predict all leukopenia cases.

inv-17: NUDT15 testing — definition and relevance

DefinitionNUDT15 testing: genetic testing for NUDT15 variants that strongly influence thiopurine tolerance and risk of hematopoietic toxicity.

Clinical implication

Policy revision history and references

1989bibliography

Lennard et al. (1989) foundational pharmacogenetics study on azathioprine toxicity and TPMT polymorphism added to bibliography.

2018bibliography

ACG Clinical Guideline (Lichtenstein et al., 2018) on management of Crohn’s disease cited as supporting evidence for TPMT/testing recommendations.

2019bibliography

Canadian Association of Gastroenterology guideline (Mack et al., 2019) for pediatric Crohn’s disease included in references.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyMetabolite Markers of Thiopurines Testing

Policy CodePolicy N/A

Change TypeNo material clinical or coverage changes

Effective DateN/A

Next Review DateN/A

Key ActionOrder TPMT (and consider NUDT15) testing prior to initiating thiopurines; use metabolite testing reactively for toxicity, inadequate response, or suspected nonadherence.

SourceLink

On This Page

ECCO/ESPGHAN and NASPGHAN cite measuring metabolites after 2–3 months to aid dose optimization in incomplete responders.

Suspected nonadherence: Thiopurine metabolite testing to assess adherence when poor compliance is suspected and results will impact clinical management.

ECCO/ESPGHAN and NASPGHAN identify metabolite testing for suspected nonadherence.

Pharmacogenetic testing (TPMT, NUDT15) and therapeutic drug monitoring

Pharmacogenetic testing and therapeutic drug monitoring are supported by guideline recommendations in the following contexts:

TPMT and NUDT15 genotyping to predict toxicity: TPMT and NUDT15 genotyping (or TPMT phenotyping) to inform initial thiopurine dosing and identify patients at increased risk of hematopoietic toxicity, including use in IBD and acute lymphoblastic leukemia (ALL).

CPIC provides dosing guidance based on TPMT and NUDT15 genotypes; BSG recommends checking TPMT in all patients considered for thiopurines and NUDT15 if available.

Management of indeterminate genotypes/phenotypes: For TPMT or NUDT15 indeterminate phenotypes, consider TPMT erythrocyte activity testing to assess phenotype and if NUDT15 is indeterminate or unknown and thiopurines are required, monitor closely for toxicity.

CPIC 2020 guidance addresses evaluation and monitoring for indeterminate phenotypes.

Therapeutic drug monitoring to guide dosing in disease-specific contexts: Use measurement of 6-TG and 6-MMP to guide dosing adjustments, optimize therapy in active disease, and investigate causes of toxicity or lack of response in IBD; apply pharmacogenetic results in conjunction with metabolite levels when making dosing decisions.

ECCO/ESPGHAN, BSG, CPIC and disease-specific guidelines support TDM and pharmacogenetic testing to predict toxicity and guide dosing.

Clinical documentation supporting testing must indicate the medical indication for the assay. Acceptable documentation includes, but is not limited to: pre-initiation TPMT testing to assess risk of severe myelosuppression, testing for suspected thiopurine toxicity or myelotoxicity, evaluation of inadequate therapeutic response on a stable thiopurine dose, or evaluation when nonadherence is suspected.

Document the clinical reason (e.g., pre-initiation TPMT testing, suspected toxicity, inadequate response, suspected nonadherence).
Include relevant labs and clinical findings (CBC, LFTs, disease activity) when applicable.

Step Therapy

Reactive (not routine) testing; no step therapy specified

Clinical guidelines emphasize reactive (for toxicity, inadequate response, or suspected nonadherence) rather than routine proactive metabolite testing for patients who are doing well on stable thiopurine therapy. No step-therapy requirements are specified by this policy.

Reactive testing recommended for active disease, toxicity, abnormal LFTs, leucopenia, or suspected nonadherence.
Routine/repetitive metabolite monitoring in asymptomatic, stable patients is generally not supported.

Denial Risk

No explicit authorization/denial triggers stated

This policy does not list explicit authorization or denial triggers beyond the general requirement to document medical indication and to comply with any payer or government authorization rules. Providers should submit sufficient clinical documentation to justify medical necessity and check for any payer-specific prior authorization rules.

No specific automatic approval/denial criteria are provided in this policy text.
Use payer portals or contact provider services to confirm authorizations.

Measure metabolites after 2–3 months when optimizing dosing in active disease per ECCO/ESPGHAN guidance.

DocumentationClinical indication should justify repeat testing (e.g., toxicity, inadequate response, suspected nonadherence).

NUDT15 variants affect tolerance in patients with ALL and inflammatory bowel disease; if NUDT15 indeterminate or unknown and thiopurines are required, monitor closely for toxicity.

Relation to TPMTNUDT15 testing complements TPMT assessment as both genes inform thiopurine dosing and risk stratification.

inv-18: Thiopurine metabolite testing — measurement of 6-TG and 6-MMP

DefinitionThiopurine metabolite testing: measurement of 6-thioguanine nucleotides (6-TG) and 6-methylmercaptopurine (6-MMP) to assess adherence, inform dose adjustments, and evaluate causes of toxicity or lack of response.

Clinical usesUsed to investigate myelotoxicity, elevated transaminases, inadequate response on stable dose, suspected nonadherence, or to optimize dosing in active disease.

Monitoring roleRecommended reactively by societies (e.g., ECCO/ESPGHAN, NASPGHAN) rather than for routine surveillance in quiescent patients.

inv-19: CPIC guideline (TPMT/NUDT15)

ResourceCPIC guideline: Clinical Pharmacogenetics Implementation Consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes.

UtilityProvides genotype-based dosing recommendations and guidance for indeterminate phenotypes (e.g., evaluate TPMT activity or closely monitor if NUDT15 unknown).

CitationRelling et al., Clin Pharmacol Ther (2019) — CPIC guideline referenced in policy bibliography.

inv-20: UpToDate: Thiopurines

ResourceUpToDate topic: 'Thiopurines — pretreatment testing and approach to therapeutic drug monitoring for adults with inflammatory bowel disease.'

ContentCovers pretreatment testing (TPMT/NUDT15) and therapeutic drug monitoring including metabolite measurement and clinical considerations.

AccessCited UpToDate entry and related ACG guideline references (Rubin et al., 2019) in the policy bibliography.

2017bibliography

American Gastroenterological Association guideline on Therapeutic Drug Monitoring (Bressler et al., 2017) cited to support reactive metabolite testing and against routine proactive monitoring.

policy_note

Procedure codes (80299, 82657, 84433) listed for reference; payer may require prior authorization per standard procedures.

regulatory_note

Policy notes that if conflict exists with government coverage (LCD/NCD/state Medicaid), the government policy will govern determinations.

bibliographyLatest

CPIC guideline and other guideline sources (BSG, NICE, UpToDate) are listed among references supporting pharmacogenetic testing recommendations.